Fortress Biotech Q2 2026 revenue up 14% to $18.7M; net loss $2.5M vs prior-year income

Fortress Biotech, Inc.

Q2 2026 net revenue $18.7M (up 14% YoY from $16.4M); net loss attributable to common stockholders $(2.5)M ($0.08/share) vs net income $13.4M ($0.50/share) in Q2 2025.
Cash and equivalents $196.6M at June 30, 2026, up from $79.4M at Dec 31, 2025, boosted by $205M PRV sale from ZYCUBO.
Crystalys closed $130M Series B financing for dotinurad; Urica holds equity and 3% royalty on future net sales.
Journey Medical expanded Emrosi payer access to over 150M commercial lives (~85% of US commercial lives); Q2 net product revenue $17.8M vs $15.0M YoY.
AstraZeneca reported anselamimab subgroup analysis: 62% survival improvement and 71% reduction in cardiovascular hospitalizations in kappa AL amyloidosis; regulatory submission planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.